Squarepoint
PLRX icon

Squarepoint’s Pliant Therapeutics PLRX Stock Holding History

Squarepoint’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.5K Sell
40,814
-122,401
-75% -$149K ﹤0.01% 4271
2026
Q1 		$206K Buy
163,215
+64,197
+65% +$81K ﹤0.01% 3949
2025
Q4 		$121K Buy
99,018
+65,176
+193% +$97.9K ﹤0.01% 4005
2025
Q3 		$50.1K Sell
33,842
-124,002
-79% -$189K ﹤0.01% 4229
2025
Q2 		$183K Buy
157,844
+4,149
+3% +$5.86K ﹤0.01% 4005
2025
Q1 		$207K Buy
153,695
+130,263
+556% +$791K ﹤0.01% 3991
2024
Q4 		$309K Sell
23,432
-2,950
-11% -$40.3K ﹤0.01% 4126
2024
Q3 		$296K Sell
26,382
-54,093
-67% -$677K ﹤0.01% 3457
2024
Q2 		$865K Buy
+80,475
New +$1.04M ﹤0.01% 2670
2023
Q3 		– Sell
-33,878
Closed -$614K – 4129
2023
Q2 		$614K Sell
33,878
-14,819
-30% -$351K ﹤0.01% 2488
2023
Q1 		$1.3M Buy
48,697
+19,852
+69% +$565K 0.01% 1713
2022
Q4 		$558K Sell
28,845
-4,487
-13% -$93.8K ﹤0.01% 2212
2022
Q3 		$696K Buy
+33,332
New +$638K ﹤0.01% 2011
2022
Q1 		– Sell
-10,188
Closed -$138K – 3363
2021
Q4 		$138K Buy
+10,188
New +$162K ﹤0.01% 2840

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Squarepoint's PLRX Position: Q2 2026 in Review

Squarepoint reduced its Pliant Therapeutics (PLRX) stake by 75% in Q2 2026, selling an estimated $149K and leaving 40,814 shares worth $46.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4271.

Squarepoint first reported a position in PLRX in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.3M in Q1 2023. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Squarepoint held 40,814 shares of Pliant Therapeutics worth $46.5K as of Q2 2026.
  • Squarepoint sold 122,401 Pliant Therapeutics shares in Q2 2026, an estimated $149K.
  • Pliant Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4271 holding.
  • Squarepoint first reported a position in Pliant Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Squarepoint's Pliant Therapeutics position peaked at $1.3M in Q1 2023.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.